Key Safety Reminder for GLP-1 Receptor Agonists
The MHRA has issued a reminder for healthcare professionals regarding glucagon-like peptide-1 receptor agonists (GLP-1RAs). This update emphasises the importance of patient counselling on potential side effects and highlights emerging concerns around misuse of these medications.
What You Need to Know
GLP-1RAs are widely prescribed for type 2 diabetes and, increasingly, for weight management in eligible patients. However, healthcare professionals should ensure patients are fully informed about:
- Common side effects: Gastrointestinal symptoms including nausea, vomiting, diarrhoea, and constipation are frequently reported, particularly during dose escalation.
- Serious adverse effects: Pancreatitis, thyroid concerns, and acute kidney injury have been documented and require careful patient monitoring.
- Misuse risk: Off-label use for cosmetic weight loss in non-diabetic individuals is increasing, often without appropriate medical supervision or monitoring.
Recommended Actions
- Ensure comprehensive patient counselling before initiating GLP-1RA therapy, covering both common and serious side effects.
- Reinforce the importance of reporting adverse events promptly.
- Be alert to signs of misuse or off-label acquisition, particularly in non-clinical settings.
- Monitor patients regularly for emerging safety signals.
- Review patient information leaflets with patients to support informed decision-making.
Affected Medications
This alert applies to all GLP-1 receptor agonists, including semaglutide, dulaglutide, liraglutide, tirzepatide, and others in this class.
Further Information
For the full MHRA drug safety update, visit the MHRA website.